TY - JOUR
T1 - Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis
AU - Sacco, Antonio
AU - Maiso, Patricia
AU - Azab, Abdelkareem
AU - Azab, Feda
AU - Zhang, Yong
AU - Liu, Yang
AU - Ngo, Hai T.
AU - Morgan, Brittany
AU - Quang, Phong
AU - Issa, Ghayas
AU - Ghobrial, Irene M.
AU - Roccaro, Aldo M.
PY - 2011/2/1
Y1 - 2011/2/1
N2 - Epigenetics represent heritable changes in gene expression that are not due to any alteration in the DNA sequence. One of the best-known epigenetic markers is histone acetylation, which has been shown to be deregulated in neoplastic diseases, including B-cell malignancies, such as Waldenström's Macroglobulinemia (WM), a low-grade B-cell lymphoma characterized by the presence of lymphoplasmacytic cells in the bone marrow and a serum monoclonal immunoglobulin M in the circulation. It has been recently demonstrated that microRNAs may be responsible for modulating histone acetylation in WM cells, thus providing the preclinical evidences for using microRNA-based therapeutic strategies in this disease.
AB - Epigenetics represent heritable changes in gene expression that are not due to any alteration in the DNA sequence. One of the best-known epigenetic markers is histone acetylation, which has been shown to be deregulated in neoplastic diseases, including B-cell malignancies, such as Waldenström's Macroglobulinemia (WM), a low-grade B-cell lymphoma characterized by the presence of lymphoplasmacytic cells in the bone marrow and a serum monoclonal immunoglobulin M in the circulation. It has been recently demonstrated that microRNAs may be responsible for modulating histone acetylation in WM cells, thus providing the preclinical evidences for using microRNA-based therapeutic strategies in this disease.
UR - http://www.scopus.com/inward/record.url?scp=79953720283&partnerID=8YFLogxK
U2 - 10.3816/CLML.2011.n.022
DO - 10.3816/CLML.2011.n.022
M3 - Article
C2 - 21454206
AN - SCOPUS:79953720283
SN - 2152-2650
VL - 11
SP - 109
EP - 111
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 1
ER -